VivoSeq
Immunology

Sjogren Syndrome

27

Pipeline Programs↗

2

Active Trials↗

21

Companies Involved↗

Sjogren syndrome is an emerging landscape with 27 programs across 21 companies. The most active players are Shanghai Escugen Biotechnology Co., Ltd, Glaxo Dba Glaxosmithkline, Immunex. 9 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

11/100

Mech. Concentration

9/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Escugen Biotechnology Co., Ltd

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2I

Immunex

1 program

Phase 2Gilead logo

Gilead

1 program

Phase 2Incyte logo

Incyte

1 program

Phase 2Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

19 of 28 classified programs — the dominant modality here.

32%ALL OTHERSMonoclonal antibody621%Protein / enzyme311%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 97% of 30 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Not yet recruiting2 · 50%

Clinical Trials

Trial Activity

Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome
Completed·—·Phase 3·NCT03865888·60 enrolled
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome
Not yet recruiting·SShanghai Escugen Biotechnology Co., Ltd·Phase 2·NCT07375524·40 enrolled
A Randomized, Double-blind, Placebo Controlled, 2-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)
Completed·Novartis logoNovartis·Phase 3·NCT05350072·275 enrolled
Safety and Efficacy of Topical Infliximab Versus Topical Steroid in Autoimmune Dry Eye Disease: Randomized Controlled Trial.
Not yet recruiting·IInstituto de Oftalmología Fundación Conde de Valenciana·Phase 2·NCT07671222·38 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)